This clinical trial is focused on studying Parkinson’s disease, a condition that affects movement and can cause symptoms like tremors, stiffness, and difficulty with balance and coordination. The trial is testing a medication called Tavapadon, which is taken as a tablet. Tavapadon is an investigational drug, meaning it is still being studied and is not yet approved for general use. The purpose of this study is to evaluate the long-term safety and tolerability of Tavapadon for people diagnosed with Parkinson’s disease.

Participants in the trial will take Tavapadon orally, which means by mouth, for a period of up to 58 weeks. During this time, researchers will monitor participants to see how they respond to the medication and to check for any side effects. The study will also look at how Tavapadon affects the symptoms of Parkinson’s disease over the long term. This includes observing changes in movement and daily activities, as well as any adjustments in the use of other medications like L-Dopa, which is commonly used to manage Parkinson’s symptoms.

The trial will involve regular check-ups, including physical and neurological examinations, to ensure participants’ safety and to gather data on the effects of Tavapadon. Researchers will also collect information through various assessments and tests to understand how the medication impacts speech and facial expressions, which can be affected by Parkinson’s disease. The study aims to provide valuable insights into the potential benefits and risks of using Tavapadon for managing Parkinson’s disease over an extended period.